John Crowley, Chairman and CEO, Amicus Therapeutics Announced as Keynote Speaker for Life Science Innovation Northwest 2013 Conference
Global Biotechnology Leader to Kick-off Pacific Northwest’s Largest Life Sciences Conference
SEATTLE – February 12, 2013 – John F. Crowley, Chairman and Chief Executive Officer, Amicus Therapeutics was announced as keynote speaker for the 2013 Life Science Innovation Northwest (LSINW) conference, scheduled for July 10 -11 at the Washington State Convention Center in Seattle.
Mr. Crowley’s involvement in the life science industry stems from the 1998 diagnosis of two of his children with Pompe disease-a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the co-founder, president and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a novel treatment for Pompe disease (which he credits as ultimately saving his children's lives.)
Many people will remember Mr. Crowley’s pursuit of a cure for Pompe Disease was chronicled in the 2010 film “Extraordinary Measures” starring Harrison Ford and Brendan Fraser as John Crowley. The film was shot in St. Paul, Tualatin and Beaverton, Oregon, as well as Vancouver, Washington.
In accepting the invitation to be this year’s LSINW keynote speaker, Mr. Crowley said, “I am very pleased to be presenting the keynote at this year’s LSINW in Seattle. The Pacific Northwest has long been known as a center of life science innovation where ultrasound and cardiac defibulators were developed in Washington. Additionally, in 2010, three of the 21 drugs approved by the FDA were discovered and developed in Seattle. This is truly an area where innovation and “coopertition” takes place among institutional research, academia and corporate entities. I hope everyone will make an effort to attend in July.”
“We’re honored to have John Crowley as the keynote speaker for this year’s LSINW conference,” said Chris E. Rivera, President, Washington Biotechnology & Biomedical Association (WBBA). “Mr. Crowley’s involvement in the conference will emphasize the importance of the Pacific Northwest as a leader in innovation in the life science community, and how the life science industry is making a dramatic impact on people’s lives.”
Earlier this month, G. Steven Burrill, Founder and CEO of Burrill & Company, was announced as a conference partner and speaker for LSINW, the fourth year in a row that Burrill and Company has partnered with the WBBA. “We also are very pleased to again partner with Burrill & Company to host the conference and we look forward to Steve’s compelling discussion of the latest in the economic and development trends in the industry and overall state of the life science industry,” Rivera said.
“In 2012, LSINW attracted nearly 1000 attendees from 15 countries around the world”, said Rivera. This year’s conference will include expert panels, over 80 presentations by public and private companies, and non-profit and research organizations specializing in medical technology, diagnostics, therapeutic innovations, and cutting-edge developments in global health from Washington, Oregon, Montana, Idaho and British Columbia. With the expanded agenda and expected increase in attendance, LSINW will continue to be the Northwest’s preeminent, must attend life science conference.
The Pacific Northwest has emerged as one of the world’s most innovative and important life science sectors. Now in its twelfth year, LSINW is expanding its reach to attract more investment and partnering representatives from all around the United States, as well as from delegations that are expected from Asia, India, Australia, Scandinavia, Canada, France, and Germany. These delegations provide opportunities to explore financial and strategic partnerships and investments with companies and organizations that attend and present at the conference.
About LSINW 2013
Life Science Innovation Northwest 2013 is presented by The Washington Biotechnology & Biomedical Association (WBBA) and Burrill & Company.
Many past attendees have shared their reasons for attending LSINW:
• Intense networking with investors, peers, business development executives, and strategic partners.
• Panel discussions that give overviews of the region’s life science industry featuring leading life sciences investment, organization and company executives.
• Podium presentations provide the opportunity to showcase organizations’ innovations and mission to potential investors and strategic partners.
• Speed dating sessions are held to foster introductions and conversations between companies and investors to initiate or facilitate fund-raising activities.
• Early stage research is demonstrated through poster sessions that provide opportunities to share cutting edge innovation with and get valuable feedback from leaders of the life science industry.
For more information on the LSINW 2013 conference, please visit www.washbio.org.
Opportunities for sponsorship are available. If you are interested in being a sponsor, please contact Dennis Kroft at firstname.lastname@example.org or 206.456.9565.
The Washington Biotechnology & Biomedical Association (WBBA) is an independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. Our members include organizations engaged in, or supportive of, research, development and commercialization of life science technologies. Our mission is to translate innovation to realization: from breakthrough discoveries to better health solutions. Learn more about the WBBA at www.washbio.org.
About Burrill & Company
Burrill & Company has established unrivaled access and visibility in the life sciences industry. With more than $1 billion in assets under management, the firm’s businesses include venture capital, private equity, merchant banking and media. A unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe and Asia. (www.burrillandco.com).
The Washington Biotechnology & Biomedical Association serves more than 450 companies, universities, academic institutions and others who represent the heart of Washington's life sciences community. Learn more at www.washbio.org.